A Phase III trial for drisapersen, a drug by GlaxoSmithKline and Prosensa for treating Duchenne muscular dystrophy, failed to meet primary goals three months after receiving breakthrough therapy designation from the U.S. FDA. The trial among 186 boys suffering from the disease failed to demonstrate significant improvement in walking distance or motor function, compared with a placebo. DMD affects one in 3,500 live male births.

Full Story:
PharmaTimes (U.K.)

Related Summaries